

Episurf Medical Q1 2025 - Solid start of 2025

Redeye provides an in-depth review of Episurf Medical's Q1 report and events during and after the quarter. The report contained no significant surprises, and the financials were largely in line with our estimates. We reiterate our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Episurf Medical Q1 2025 - Solid start of 2025